deltatrials
Recruiting PHASE2 NCT05650229

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Adaptive Study of the Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

Sponsor: Abliva AB

Conditions Primary Mitochondrial Disease
Interventions KL1333 Placebo
Updated 15 times since 2023 Last updated: Oct 8, 2025 Started: Dec 13, 2022 Primary completion: Oct 31, 2027 Completion: Nov 30, 2027

Listed as NCT05650229, this PHASE2 trial focuses on Primary Mitochondrial Disease and remains actively recruiting participants. Sponsored by Abliva AB, it has been updated 15 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

15 versions recorded

  1. Nov 2025 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2025 — Nov 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

  4. May 2025 — Jul 2025 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  5. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 10 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  5. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  6. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  7. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  8. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  9. Feb 2023 — May 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Jan 2023 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abliva AB
Data source: Abliva AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Barcelona, Spain, Bologna, Italy, Bordeaux, France, Brussels, Belgium, Cambridge, United Kingdom, Copenhagen, Denmark, Ghent, Belgium, Houston, United States, Leuven, Belgium and 10 more location s